Last reviewed · How we verify

Oral iron tablets

NICHD Global Network for Women's and Children's Health · Phase 3 active Small molecule

Oral iron tablets is a Iron supplement Small molecule drug developed by NICHD Global Network for Women's and Children's Health. It is currently in Phase 3 development for Iron deficiency anemia in pregnant women, Iron deficiency anemia in children. Also known as: Ferrous Sulfate.

Oral iron tablets replenish depleted iron stores and restore hemoglobin synthesis to treat iron deficiency anemia.

Oral iron tablets replenish depleted iron stores and restore hemoglobin synthesis to treat iron deficiency anemia. Used for Iron deficiency anemia in pregnant women, Iron deficiency anemia in children.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameOral iron tablets
Also known asFerrous Sulfate
SponsorNICHD Global Network for Women's and Children's Health
Drug classIron supplement
ModalitySmall molecule
Therapeutic areaHematology
PhasePhase 3

Mechanism of action

Iron is an essential mineral required for hemoglobin production in red blood cells. Oral iron supplementation provides bioavailable iron that is absorbed in the gastrointestinal tract, allowing the body to synthesize adequate hemoglobin and restore oxygen-carrying capacity of blood. This is particularly important in pregnant women and children where iron deficiency anemia can impair development and health outcomes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral iron tablets

What is Oral iron tablets?

Oral iron tablets is a Iron supplement drug developed by NICHD Global Network for Women's and Children's Health, indicated for Iron deficiency anemia in pregnant women, Iron deficiency anemia in children.

How does Oral iron tablets work?

Oral iron tablets replenish depleted iron stores and restore hemoglobin synthesis to treat iron deficiency anemia.

What is Oral iron tablets used for?

Oral iron tablets is indicated for Iron deficiency anemia in pregnant women, Iron deficiency anemia in children.

Who makes Oral iron tablets?

Oral iron tablets is developed by NICHD Global Network for Women's and Children's Health (see full NICHD Global Network for Women's and Children's Health pipeline at /company/nichd-global-network-for-women-s-and-children-s-health).

Is Oral iron tablets also known as anything else?

Oral iron tablets is also known as Ferrous Sulfate.

What drug class is Oral iron tablets in?

Oral iron tablets belongs to the Iron supplement class. See all Iron supplement drugs at /class/iron-supplement.

What development phase is Oral iron tablets in?

Oral iron tablets is in Phase 3.

What are the side effects of Oral iron tablets?

Common side effects of Oral iron tablets include Gastrointestinal upset (nausea, abdominal discomfort), Constipation, Dark stools, Diarrhea, Metallic taste.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing